A randomized phase II trial of adjuvant trastuzumab emtansine (T-DM1) followed by subcutaneous trastuzumab versus paclitaxel in combination with subcutaneous trastuzumab for Stage I HER2-positive breast cancer (ATEMPT 2.0)
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Dana-Farber Cancer Institute
Start Date
February 14, 2023
End Date
February 28, 2028
Administered By
Duke Cancer Institute
Awarded By
Dana-Farber Cancer Institute
Start Date
February 14, 2023
End Date
February 28, 2028